Study on the diagnostic value of VEGF, CA19-9 and CEA in pancreatic cancer and the risk factors of vascular invasion

Abstract

Background: Pancreatic cancer is a malignant tumor of the gastrointestinal tract. Due to its insidious onset, most patients with newly diagnosed pancreatic cancer have missed the opportunity for radical surgery, which offers patients the best chance of survival. The 5-year survival rate of patients with pancreatic cancer can be improved with early diagnosis, and serum tumor makers are an inexpensive and convenient diagnostic tool that is widely used in the diagnosis of malignancies. Objective: To determine the diagnostic value of vascular endothelial growth factor (VEGF), carbohydrate antigen 19-9 (CA 19-9), and carcinoembryonic antigen (CEA) in patients with pancreatic cancer and the risk factors of vascular invasion. Methods: An experimental group comprising 52 patients with pancreatic cancer admitted to our department from July 2021 to July 2022 and a control group comprising 21 patients with benign pancreatic diseases during the same period were included in our study. Their serum VEGF, CA 19-9, and CEA levels were detected and compared between the two groups, and the correlation between the three markers in the invaded vessel and non-invaded vessel groups was investigated. The diagnostic value of a single tumor marker and in combination for pancreatic cancer was analyzed, and the three tumor marker levels of the experimental group in different pathological characteristics were detected and compared. Results: The experimental group had higher serum VEGF, CA 19-9, and CEA levels than the control group (P < 0.05). Through a receiver operating characteristic (ROC) curve analysis, the combined detection had the highest value for the diagnosis of pancreatic cancer, in which the area under the curve (AUC) was 0.9158 (95% CI: 0.8415–0.9900), while the sensitivity and specificity were 76.19% and 98.08%, respectively. Serum VEGF and CA 19-9 levels were higher in stage III–IV pancreatic cancer patients and those with tumor metastasis compared with stage I–II patients and those without metastasis (P < 0.05), respectively. Binary logistic regression analysis was performed to determine the risk factors of vascular invasion in pancreatic cancer, and the results showed that only serum VEGF was a risk factor (P < 0.05), OR (95% CI): 1.001–1.006. Conclusion: Patients with pancreatic cancer have significantly higher serum VEGF, CA 19-9, and CEA levels, and the combined detection of tumor markers is of high clinical value in its diagnosis. In addition, serum VEGF is an independent risk factor of vascular invasion in pancreatic cancer, which can predict vascular invasion to a certain extent.